Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 1/20 | 0.54 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.54 |
| ▸ | GRM5 | P41594 | 2/20 | 0.54 |
| ▸ | XDH | P47989 | 1/20 | 0.51 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | KDM5A | P29375 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | CHUK | O15111 | 1/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | GRK6 | P43250 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4772289 | 0.84 | MCL1 (0.44) | SLC22A12ABCG2KDM5A | |
| SCHEMBL31663577 | 0.83 | CLK4 (0.53) | F11PIN1GRM5ABCG2 | |
| SCHEMBL5604793 | 0.83 | CLK4 (0.53) | F11PIN1GRM5ABCG2 | |
| SCHEMBL4775974 | 0.81 | CYP11B2 (0.42) | F11PIN1XDHSLC22A12 | |
| SCHEMBL4779457 | 0.78 | KMO (0.51) | PIN1GRM5 | |
| SCHEMBL4775929 | 0.78 | MCL1 (0.38) | SMN1; SMN2 | |
| SCHEMBL1795533 | 0.78 | GRM5 (0.57) | GRM5NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3090482 | 0.77 | ALOX15 (0.41) | F11PIN1GRM5NPC1RAB9A | |
| SCHEMBL4776002 | 0.77 | MYC (0.50) | GRM5XDHABCG2KDM5ASMN1; SMN2 | |
| SCHEMBL4772052 | 0.77 | ALOX15 (0.46) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1987003-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-11-05 | — | — | EP | claimed |
| WO-2007093542-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | claimed |
| US-20070197553-A1 | 4-Aryl-pyridine-2-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | claimed |
| CN-101384554-B | Pyridine-2-carboxamide derivatives | HOFFMANN LA ROCHE | 2012-08-08 | — | — | CN | disclosed |
| CN-101384554-A | Pyridine-2-carboxamide derivatives | HOFFMANN LA ROCHE (CH) | 2009-03-11 | — | — | CN | disclosed |
| EP-1987003-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093542-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| US-20070197553-A1 | 4-Aryl-pyridine-2-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197553-A1 | 4-Aryl-pyridine-2-carboxyamide derivatives | GRM2, GRM1, GRM3 | F11 3718/4885PIN1 3693/4885GRM5 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.